Skip to content
Peptide Atlas
All peptides

Matrixyl

Tier 2 · Preclinical
Also known as Palmitoyl pentapeptide-4 · Pal-KTTKS · Matrixyl 3000

The strongest evidence is Tier 1 human randomized controlled trials, including the Robinson et al. (2005) 12-week double-blind placebo-controlled split-face study (n=93), Lintner et al. (n=94, PMID 17696523), Aruan et al. (2023, n=21), Kaur et al. (n=48), Scherdin et al. (n=125), and several Sederma (manufacturer) pivotal trials, plus a 2018 systematic review citing 10+ RCTs in 1,000+ subjects. However, much of the mechanistic and dermal-delivery evidence is Tier 2 (in vitro human fibroblast cultures and rodent models). Clinical trials are generally small, frequently manufacturer-linked, and predominantly conducted in Caucasian women (only Aruan 2023 studied Asian skin). Reported effect sizes and penetration figures vary widely, and several notable claims rest on single, lower-tier sources.

Half-life
Not recorded
Routes
Topical
Goals
Anti-aging / skin rejuvenation · Wrinkle and fine line reduction · Skin firmness and elasticity · Wound healing (preclinical)
Cost / mg
Not recorded

How it works

Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a lab-made peptide made by attaching a fatty acid (palmitic acid) to a five-amino-acid chain (KTTKS) originally found as a fragment of type I collagen. It acts as a 'matrikine' — a messenger peptide that signals skin cells called fibroblasts to behave as if collagen has been damaged and needs rebuilding. In response, fibroblasts increase production of collagen, fibronectin, and other components of the skin's supportive matrix. The attached fatty acid makes the otherwise water-loving peptide able to slip through the skin's oily outer barrier to reach the dermis. In human trials this translates into modest, measurable reductions in wrinkles and improvements in skin texture and firmness, with very good tolerability.

Overview

Overview

Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide consisting of the pentapeptide lysine-threonine-threonine-lysine-serine (KTTKS) conjugated to palmitic acid, a 16-carbon saturated fatty acid. It is also known as palmitoyl pentapeptide-3, Pal-KTTKS, and Micro-Collagen. (Matrixyl 3000 is a separate, related product — a combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 — not another name for palmitoyl pentapeptide-4.) Most sources give a molecular formula of C39H75N7O10 and molecular weight of approximately 802 g/mol (CAS 214047-00-4, PubChem CID 9897237), although one source reports ~678 Da for the core peptide and ~1,000 Da with the lipid modification.

Matrixyl was developed by Sederma SAS (now part of Croda International) and launched in 2000 as the first peptide active ingredient specifically designed for anti-aging cosmetic applications. It appears in over 1,500 commercial skincare products worldwide.

Origin and Rationale

The KTTKS sequence was originally identified in 1993 by Katayama et al. at the University of Tennessee as a subfragment of the C-terminal propeptide of type I procollagen. It was determined to be the minimum sequence capable of retaining approximately 80% of the parent fragment's activity in stimulating extracellular matrix production by human dermal fibroblasts. In the original screening work, subfragments R9 and R11 stimulated collagen and fibronectin production 6–8 fold in human lung fibroblasts before KTTKS was pinned down as the minimum active sequence.

Matrixyl belongs to the class of signal peptides known as matrikines — messenger peptides derived from extracellular matrix proteins that regulate cell activity through specific receptor interactions. By mimicking a fragment of degraded collagen, it signals fibroblasts to increase collagen synthesis. The palmitoyl modification was introduced by Lintner and colleagues at Sederma to overcome the poor skin permeation of the unmodified hydrophilic pentapeptide; the reported magnitude of penetration enhancement is contested, ranging from 5–10 fold to 100–1000 fold across sources.

Mechanism

In vitro, Matrixyl stimulates dermal fibroblast production of collagen types I, III, and IV, fibronectin, and glycosaminoglycans in a dose- and time-dependent manner, with effects evident within about 4 hours. Proposed mechanisms include activation of fibroblast surface receptors triggering MAPK/ERK signaling, mild inhibition of matrix metalloproteinases (MMPs), and (per one source) interaction with TGF-beta receptors with stimulation of hyaluronic acid synthesis. However, the precise receptor target remains unidentified, and several downstream mechanisms (epidermal thickening, GAG inhibition, TGF-beta interaction) are expert-opinion or theoretical rather than demonstrated in humans. C16-KTTKS also self-assembles into nanotape structures, and this self-assembly is linked to its collagen-stimulating activity.

Clinical Evidence

The pivotal human trial is Robinson et al. (2005), a 12-week double-blind, placebo-controlled, split-face study of 93 women aged 35–55, in which a moisturizer containing just 3 ppm (0.0003%) Pal-KTTKS applied twice daily produced significant improvements in wrinkle and fine-line reduction versus moisturizer alone, confirmed by quantitative image analysis and expert graders. A companion head-to-head evaluation reported that Matrixyl matched retinol's wrinkle reduction (~20% vs 17%) with zero irritation, while 40% of the retinol group experienced erythema.

Additional trials — including Lintner et al. (n=94, PMID 17696523), Kaur et al. (n=48), Scherdin et al. (n=125, dose-dependent periorbital improvement), Aruan et al. (2023, n=21, the only trial in Asian skin), and several Sederma studies — reported reductions in wrinkle depth, fold thickness, and skin rigidity, along with histological changes including increased elastin density and dermal-epidermal junction remodeling. A 2018 systematic review found moderate efficacy (10–30% wrinkle reduction versus baseline). Cited effect sizes vary widely (from ~10–30% up to 45% for deep wrinkles with Matrixyl 3000 and 68% at 4 ppm in a single lower-tier source), with higher figures often from vendor-linked sources.

Related Variants

  • Matrixyl 3000 combines palmitoyl tripeptide-1 (pal-GHK, collagen stimulation) and palmitoyl tetrapeptide-7 (pal-GQPR, reduces inflammation via lower IL-6).
  • Matrixyl Synthe-6 (palmitoyl tripeptide-38) is reported to stimulate collagens I, III, and IV, fibronectin, hyaluronic acid, and laminin-5.

Preclinical / Other Findings

Animal and in vitro work has explored Matrixyl in wound healing (accelerated closure, increased collagen deposition, improved angiogenesis in rodent models), tendon cells (increased type I collagen and TGF-beta), reduction of myofibroblast trans-differentiation, and combination with i-PRF (the study's strongest synergy was with a different peptide, GEKG). Novel KTTKS conjugates (ionic-liquid IL-KTTKS) showed antibacterial, antifungal and collagenesis-inducing action, and palmitoyl KTTKS peptides act as potent plasmin inhibitors. Effects are considered more modest than prescription retinoids and are cosmetic in nature, delivering measurable but not deep remodeling improvements.

What the research shows

92 findings extracted from the 15 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 4 human trial findings, 1 human study finding, 8 animal findings, 4 in vitro findings and 1 expert opinion finding.

  • human trialPal-KTTKS at 3 ppm provided significant improvement vs. placebo control for reduction in wrinkles/fine lines by quantitative technical analysis2

  • human trialPal-KTTKS at 3 ppm provided significant improvement vs. placebo control for reduction in wrinkles/fine lines by expert grader image analysis2

  • human trialSubjects reported significant fine line/wrinkle improvements in self-assessments2

  • human trialSubjects noted directional effects for other facial improvement parameters in self-assessments2

  • human studyThe two lipopeptides stimulate collagen production in Human Dermal Fibroblasts (HDFa) at low concentration1

  • animalIn cellular and animal photoaging experiments, GAO/PAL-4-SM possessed remarkable capabilities in boosting collagen and hyaluronic acid regeneration, mitigating inflammation and apoptosis, accelerating macrophage M2 polarization, thereby lessening skin wrinkles and leveraging elasticity3

  • animalKTTKS-CBC composites exhibited significantly better wound healing capability with alleviated inflammation, increased collagen deposition, improved angiogenesis, and accelerated wound closure in rat burn wound model6

  • animalMSC-KTTKS-CBC composites showed the best wound-healing performance among all treatment groups in rat model6

Show 10 more findings

  • animalMatrixyl (MTI) can lead to a faster healing process9

  • animalWound healing was improved from 63.5 up to 81.81% in treatment groups compared to negative control group9

  • animalC-MTI-1 and P-MTI-1 had a larger impact on wound healing compared to positive control group (Comfeel)9

  • animalRejuvenation of skin appendage was visible in both groups of cream and patches with MTI9

  • animalRe-epithelialization had a higher range for patch with MTI in comparison with cream containing MTI and positive control9

  • in vitroMatrixyl alone led to effects on human dermal fibroblast viability and proliferation4

  • in vitroWhen delivered with PC liposomes, pal-KTTKS stimulated collagen production more than free pentapeptide5

  • in vitroPC liposome-delivered pal-KTTKS stimulated collagen production more than 1 mM ascorbic acid positive control5

  • in vitroα-SMA-positive stress fibers per field decreased twofold with 0.1 µM Pal-KTTKS treatment (75 ± 7.1 vs 38.6 ± 16.1%)12

  • expert opinionSigal peptides have garnered remarkable efficacy in rejuvenating photoaged skin and delaying senescence3

How it works

Based on 5 animal findings, 30 in vitro findings, 2 expert opinion findings and 1 theoretical finding.

  • animalpal-KTTKS incorporated into carboxylated cellulose stimulates collagen synthesis6

  • animalDDKT enhanced collagen deposition and by day 20 DDKT-treated groups had developed dense collagen network accompanied by regenerated epidermis7

  • animalNumber of blood vessels in DDKT-treated diabetic wounds was significantly higher than in control groups with substantially enhanced neovascularization7

  • animalDDKT exhibits remarkable pro-vascularization capability7

  • animalThe contribution of MTI to collagen formation during wound healing depends on its mode of delivery and its release over time9

  • in vitroLipopeptide C-KTTKS self-assembles into nanotapes based on a multi-bilayer stacking across a pH range pH 4-7 and micelles at pH 21

  • in vitroC-RTTRS forms a substantial population of spherical micelles for the acetate salt for pH 2-7, but mainly nanotapes for the TFA salt for pH 4-71

  • in vitroNo significant effect of the counterion was noted on cell viability or collagen production1

Show 30 more findings

  • in vitroGAO ILs facilitated PAL-4 permeation by enhancing its miscibility and interaction with stratum corneum (SC)3

  • in vitroMatrixyl (palmitoyl pentapeptide-4) is studied for its ability to stimulate collagen synthesis and remodel the extracellular matrix4

  • in vitroi-PRF combined with Matrixyl increased cell viability and upregulated ECM-related genes at 72 h4

  • in vitroThe combination of i-PRF + Matrixyl showed synergistic effects on dermal fibroblasts4

  • in vitroInclusion of amphiphilic N-palmitoyl-KTTKS peptide within phospholipid-based vesicles could improve peptide stability and skin delivery5

  • in vitroIL-KTTKS conjugates present potent activity against antibiotic-susceptible strains and multidrug resistant clinical isolates of Gram-positive and Gram-negative bacterial species8

  • in vitroIL-KTTKS antibacterial activity is preserved in simulated wound fluid8

  • in vitroIL-KTTKS collagenesis-inducing effects are comparable to or stronger than those of Matrixyl8

  • in vitroIL-KTTKS exert triple antibacterial, antifungal, and collagenesis-inducing action8

  • in vitroKTTKS minimally crosses the skin because of hydrophilicity10

  • in vitroPalmitoylation demonstrated sharp peaks in the XRD pattern of KTTKS10

  • in vitroKTTKS is a matrikine that originates from the proteolytic hydrolysis of collagen11

  • in vitroKTTKS stimulates ECM production and types I and III collagen expression in vitro11

  • in vitroPal-KTTKS (palmitoyl pentapeptide-3) is a more stable form of KTTKS11

  • in vitroPalmitoyl peptides were the most active plasmin inhibitors, whether in acid or amide form11

  • in vitroNo biological effects of lysine modification to arginine in the synthesized peptides were found11

  • in vitroThree peptide compounds showed cell growth in fibroblast tests11

  • in vitroThree compounds showed no concentration-activity relationship in the collagen and DNA biosynthesis assays11

  • in vitroPalmitoyl-pentapeptide (Pal-KTTKS) is a lipidated subfragment of type 1 pro-collagen (residues 212-216)12

  • in vitroPal-KTTKS at 0.1 µM reduces α-SMA expression and trans-differentiation of fibroblasts to myofibroblast12

  • in vitroThe inhibitory effect of Pal-KTTKS on α-SMA-positive stress fibers was not significant at 0.5 µM treatment12

  • in vitroThe degree of reduction in fibroblast to myofibroblast trans-differentiation is dose-dependent12

  • in vitroStress fiber level and collagen contractility correlates with α-SMA expression level12

  • in vitroWhen protease inhibitors were added, the stability of both compounds (KTTKS and pal-KTTKS) improved significantly13

  • in vitroC16-KTTKS (Matrixyl) stimulates collagen production in human dermal and corneal fibroblasts in a concentration-dependent manner14

  • in vitroStimulation of collagen production is related to self-assembly of C16-KTTKS into nanotape structures14

  • in vitroPal-KTTKS (Matrixyl) was identified through gene expression profiling and in vitro human skin cell culture screening as a cosmetic compound affecting matrix production in aging skin15

  • expert opinionPalmitoyl pentapeptide (pal-KTTKS) is a synthetic topical agent designed to stimulate collagen production and provide anti-wrinkle benefits2

  • expert opinionMatrixyl (PP4) has collagenesis-inducing effects8

  • theoreticalSigal peptides have low solubility and poor permeability which presents a challenge in their transdermal delivery3

Dosing

Based on 1 animal finding.

  • animalTherapeutic dressings were renewed every 5 days6

How the body handles it

Based on 4 animal findings and 12 in vitro findings.

  • animalBoth KTTKS and pal-KTTKS were rapidly degraded in skin extracts and homogenates, but pal-KTTKS was more stable than KTTKS13

  • animalNeither KTTKS nor pal-KTTKS was detected in the receptor solution, indicating neither compound could permeate through full-thickness hairless mouse skin13

  • animalKTTKS was not detected in any skin layers (stratum corneum, epidermis, and dermis)13

  • animalpal-KTTKS was observed in all skin layers with concentrations of 4.2 ± 0.7 μg/cm² in stratum corneum, 2.8 ± 0.5 μg/cm² in epidermis, and 0.3 ± 0.1 μg/cm² in dermis13

  • in vitroGAO can significantly improve the sparingly soluble properties of palmitoyl pentapeptide-4 (PAL-4)3

  • in vitroThe permeation and subcutaneous retention of PAL-4 are significantly promoted with 10wt.% GAO-SM3

  • in vitroREV and TLE methods allowed for the formation of homogeneous liposome dispersions with PdI < 0.205

  • in vitroREV method produced mean hydrodynamic diameters of <100 nm5

Show 8 more findings

  • in vitroTLE method produced mean hydrodynamic diameters of <200 nm5

  • in vitroLiposomes had net negative surface charge5

  • in vitroPercentage of structured phospholipids higher than 90%5

  • in vitroKTTKS and Pal-KTTKS decomposed at about 154 and 150°C respectively10

  • in vitroKTTKS was freely soluble in water at room temperature with logP = -1.6 ± 0.15, indicating hydrophilic nature10

  • in vitrologP of Pal-KTTKS was calculated to be about 3.7, indicating a lipophilic compound10

  • in vitroPal-KTTKS showed surface activity with a CMC value of 0.024 ± 0.004 mM10

  • in vitroKTTKS did not show surface activity10

Safety and side effects

Based on 1 human trial finding, 1 animal finding and 3 in vitro findings.

  • human trialPal-KTTKS was well tolerated by the skin2

  • animalpal-KTTKS-enriched composites supported cell adhesion and proliferation and showed good biocompatibility6

  • in vitroBoth lipopeptides show good cytocompatibility to fibroblasts at sufficiently low concentration1

  • in vitroCycloalkane lipopeptides show excellent compatibility with dermal fibroblasts7

  • in vitroNone of the synthesized peptides was cytotoxic on fibroblasts11

What people use it for

Based on 1 human study finding, 4 animal findings, 2 in vitro findings, 1 expert opinion finding and 2 theoretical findings.

  • human studyC-KTTKS is known commercially as Matrixyl and is used in cosmetic formulations as it can stimulate collagen production1

  • animalCompounds bearing one or two cyclododecyl chains (DKT and DDKT) show wound healing in diabetic rats7

  • animalDDKT showed markedly enhanced wound healing compared to DKT in diabetic rats7

  • animalDDKT-treated rat groups displayed significantly increased amount of regenerated hair follicles and faster healing process compared to control group7

  • animalpal-KTTKS had greater stability and permeability than un-modified KTTKS and may be a useful anti-wrinkle and anti-aging cosmeceutical agent13

  • in vitroCollagen pentapeptide (Lys-Thr-Thr-Lys-Ser, KTTKS) and its palmitoylated derivative (pal-KTTKS) have received attention as cosmeceutical ingredients for anti-wrinkle effects13

  • in vitroPal-KTTKS can be used in cosmetic formulations to aid improvements in the appearance of aged skin, including improved appearance of fine lines and wrinkles15

  • expert opinionPalmitoyl derivative of pentapeptide-4 (KTTKS) is the well-known cosmeceutical ingredient Matrixyl8

Show 2 more findings

  • theoreticalPalmitoyl derivative palmitoyl-KTTKS (Pal-KTTKS) is used in cosmetic products10

  • theoreticalC16-KTTKS is used in antiwrinkle cosmeceutical applications under the trade name Matrixyl14

Other findings

Based on 3 in vitro findings and 1 theoretical finding.

  • in vitroKTTKS and Pal-KTTKS did not show a melting point before decomposition10

  • in vitroMaximum UV absorbance of peptides was less than 200 nm10

  • in vitroBoth peptides showed birefringence, irregular flake morphologies, and hygroscopicity10

  • theoreticalLipopeptides bearing cycloalkane chains conjugated to the collagen-stimulating pentapeptide KTTKS are used in Matrixyl formulations7

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Much of the mechanistic and dermal-delivery evidence is in vitro or animal, not human trials

Many mechanism and penetration claims (collagen stimulation, self-assembly, α-SMA reduction, wound healing) come from in vitro fibroblast cultures and rodent models (Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides. through Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts.). One animal study (Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).) found neither KTTKS nor pal-KTTKS permeated through full-thickness skin at all, and both peptides were rapidly degraded in skin, tempering assumptions about dermal delivery.

Contested

Reported molecular weight of the peptide differs across sources

Most sources give ~802 g/mol for Pal-KTTKS (C39H75N7O10), but Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments reports ~678 Da for the core peptide and ~1,000 Da with lipid modification.

Limited evidence

Precise receptor/mechanism remains unconfirmed and mechanisms are partly theoretical

Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments explicitly notes the precise receptor target remains unidentified. Several mechanistic claims (MAPK/ERK signaling, TGF-beta receptor interaction, epidermal thickening, GAG inhibition) are tagged expert_opinion or theoretical rather than demonstrated in humans, and one source attributes TGF-beta receptor interaction (Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity) which others do not.

Single source

Some notable claims rest on a single source

The claims that Matrixyl is safe during pregnancy and causes no sensitization even at high concentrations (Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity), the 68% wrinkle-depth reduction figure (Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity), the CIR/EU SCCS regulatory determinations (Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments), and the 100-200% collagen increase in explants (Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments) each appear in only one source, several of which are lower-tier (tier 3).

Limited evidence

Clinical trials are small and dominated by manufacturer-linked studies

Pivotal human trials involved small samples (typically 15-125 subjects), several are Sederma (manufacturer) studies, and only one trial (Aruan et al. 2023) specifically studied Asian/non-Caucasian skin. The core Robinson 2005 trial used 93 Caucasian women.

Other

Nomenclature and residue-numbering inconsistencies across sources

The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. refers to Pal-KTTKS as palmitoyl pentapeptide-3 while other sources call it palmitoyl pentapeptide-4; sources also cite different procollagen residue ranges (197-241 in Matrixyl (Palmitoyl Pentapeptide-4): Research Evidence & Safety Profile | PeptideInsight vs 212-216 in Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression.).

Single source

The widely repeated claim that Matrixyl matched retinol for wrinkle reduction (about 20% versus 17%) with no irritation, while 40% of retinol users developed redness, cannot be traced to a verifiable primary study.

These head-to-head figures appear on cosmetic vendor pages (Peptidings and PeptidesClarity), which attribute them to a 50-subject 'Robinson et al. (2005)' trial that supposedly pitted Matrixyl against retinol with a vehicle control. The actual peer-reviewed pal-KTTKS trial indexed in PubMed was a different design: 93 Caucasian women aged 35–55 in a 12-week, double-blind, placebo-controlled, split-face study comparing a moisturizer containing 3 ppm pal-KTTKS against the same moisturizer alone. It reported that pal-KTTKS was well tolerated and significantly reduced wrinkles and fine lines versus placebo — but it made no comparison to retinol and reported no erythema rate. The 50-subject retinol head-to-head producing the 20%-versus-17% and 40%-erythema numbers cannot be tied to that published trial, so the retinol comparison should be treated as unconfirmed rather than as an established result.

Using it with other compounds

Check a stack
  • Palmitoyl Tripeptide-1Complementary

    May be complementary

    Both are palmitoylated matrikine peptides that drive fibroblasts to make more collagen and rebuild the dermal matrix, but they come from different collagen fragments and hit the pathway somewhat differently (Matrixyl/Pal-KTTKS via a fibroblast matrikine/TGF-beta route; Pal-GHK via broad gene modulation and MMP suppression). Because they converge on the same skin-firming, wrinkle-reducing outcome through non-identical routes, they are frequently layered together in topical formulas and are considered additive rather than redundant.

    Tier 3Largely anecdotal — commonly discussed

    Timing Topical use — can be applied together in the same routine.

    Shares collagen synthesis · dermal matrix · tissue repair

  • Palmitoyl Tetrapeptide-7Complementary

    May be complementary

    These two work as a classic cosmetic pair: Matrixyl actively builds new collagen and matrix, while Palmitoyl Tetrapeptide-7 calms inflammatory cytokines (IL-6, IL-1β) and protects the existing matrix from MMP-driven breakdown. One adds new material, the other prevents its degradation, so combining them addresses both sides of the collagen balance in aging skin.

    Tier 3Largely anecdotal — commonly discussed

    Timing Topical use — designed to be co-formulated and applied together.

    Shares dermal matrix

  • TB-500Complementary

    No documented conflict

    TB-500 supports the cell-migration and ECM-remodeling side of repair, while Matrixyl (a topical collagen matrikine) stimulates collagen I/III/IV and fibronectin production. They target different steps of matrix rebuilding \u2014 one systemic, one topical \u2014 so they complement rather than overlap.

    Tier 4Theoretical — not established

    Shares tissue repair

  • PTD-DBMComplementary

    No documented conflict

    PTD-DBM drives collagen (including collagen III) via Wnt/beta-catenin activation in dermal cells, while Matrixyl (Pal-KTTKS) is a matrikine that signals fibroblasts through MAPK/ERK to make collagen I, III and IV. They stimulate collagen by different upstream signals, so pairing them for skin firmness is a plausible non-redundant combination.

    Tier 4Theoretical — not established

    Timing Both are topical cosmetic peptides and can be used in the same skincare regimen.

    Shares collagen synthesis · dermal matrix · tissue repair

  • GLOWComplementary

    May be complementary

    Matrixyl is a topical matrikine (Pal-KTTKS) that signals fibroblasts to build type I/III collagen through the MAPK/ERK matrikine route — a different mechanism from GLOW's copper-driven and BPC/TB-driven repair. Used as a topical alongside systemic GLOW, the two converge on collagen and dermal firmness from separate angles, which is a sensible complementary skin-quality pairing.

    Tier 4Theoretical — not established

    Timing Topical Matrixyl and systemic GLOW act in different compartments; no timing conflict.

    Shares collagen synthesis · dermal matrix · tissue repair

  • ElafinComplementary

    May be complementary

    Matrixyl stimulates collagen and ECM production while inhibiting matrix-degrading proteases; elafin adds antiprotease protection of elastin/collagen by blocking neutrophil elastase. Complementary matrix-building plus matrix-protecting actions in skin repair.

    Tier 4Theoretical — not established

    Shares dermal matrix · tissue repair

  • ArgirelineComplementary

    May be complementary

    These attack expression lines from two different angles: Argireline relaxes the muscle movement that creates dynamic wrinkles, while Matrixyl (Pal-KTTKS) stimulates fibroblasts to build type I/III collagen and matrix, addressing the structural/static component of aging skin. Combining a muscle-signaling peptide with a collagen-building matrikine is a classic complementary topical pairing.

    Tier 4Theoretical — not established

    Shares collagen synthesis

  • LeuphasylComplementary

    May be complementary

    These target skin aging through completely different routes: Leuphasyl relaxes the muscle movement that etches expression lines, while Matrixyl (Pal-KTTKS) signals fibroblasts to build collagen and rebuild the dermal matrix. Combining a muscle-relaxer with a matrix-builder addresses both dynamic and structural wrinkles, a common complementary cosmetic pairing.

    Tier 3Largely anecdotal — commonly discussed

    Timing Topical; apply together or layer.

    Shares dermal matrix

Safety and side effects

Safety and Tolerability

Matrixyl/Pal-KTTKS is consistently described as well tolerated. In published trials there were no serious adverse events, and no increased skin redness or barrier damage compared to retinoid-based anti-aging agents. In the head-to-head comparison against retinol, Matrixyl produced zero irritation while 40% of the retinol group experienced erythema.

Reported adverse events (mild and uncommon)

  • Skin irritation / erythema (~1–3%)
  • Allergic contact dermatitis (<1%)
  • Sensitivity (<2%), typically resolving with discontinuation
  • Pruritus and contact dermatitis (rare)

Systemic exposure

Systemic absorption is considered negligible with topical application, and no systemic side effects have been reported. Neither KTTKS nor pal-KTTKS was cytotoxic to fibroblasts in vitro, and both show good cytocompatibility at sufficiently low concentrations.

Contraindications

  • Absolute: known hypersensitivity to palmitoyl peptides
  • Relative: active dermatitis or open wounds at the application site

One source states Matrixyl is safe to use during pregnancy (unlike retinol) and suitable for sensitive skin types that cannot tolerate retinoids — but this rests on a single lower-tier source and should be interpreted with caution.

Regulatory status

Matrixyl is not FDA-approved as a drug; it is marketed and regulated as a cosmetic ingredient (one source describes it as handled as a research compound). The Cosmetic Ingredient Review determined it safe as used (2007), and the EU SCCS reportedly found no safety concerns at concentrations up to 10% (a single-source claim).

Evidence caveats

Much mechanistic and delivery evidence is in vitro or animal-derived. Notably, one animal study found neither KTTKS nor pal-KTTKS permeated through full-thickness skin, and both were rapidly degraded in skin, tempering assumptions about dermal delivery. Clinical trials are small and often manufacturer-linked, and predominantly studied Caucasian women.

Reconstitution and handling

Preparation and Use

Matrixyl is a topical cosmetic active applied to the skin as a cream or serum. It is not an injectable peptide and does not require reconstitution or injection — unlike research peptides supplied as lyophilized powder for reconstitution with bacteriostatic water.

Supply and formulation

Matrixyl raw material is typically supplied as a solution in a glycerin/water base (by Sederma). Formulation vehicles ideally use serum, cream, or emulsion bases with lipophilic carriers to enhance penetration through the lipid-rich stratum corneum. In vitro, delivery with phosphatidylcholine (PC) liposomes enhanced collagen stimulation beyond free peptide and beyond a 1 mM ascorbic acid positive control.

Concentrations

  • Commercial formulations contain 50–500 ppm Matrixyl, though the active peptide is typically incorporated at effective concentrations of about 3–5 ppm.
  • Sources cite differing formulation concentration ranges (e.g., 0.3–0.5%, 2–5%, or 0.5–5% in topical vehicle).
  • The pivotal Robinson (2005) trial used just 3 ppm (0.0003%) twice daily.

Application

  • Apply twice daily (morning and evening), typically after serums and before moisturizer.
  • A minimum of 8–12 weeks of consistent use is generally required for visible effects.
  • For enhanced delivery, microneedling can create temporary channels that bypass the outer barrier to help peptides reach deeper dermal layers where fibroblasts reside.

Storage and stability

Matrixyl is stable under standard cosmetic formulation conditions. Store at room temperature away from direct sunlight; formulation stability is about 12–24 months. Both KTTKS and pal-KTTKS decompose around 150–154 °C without a defined melting point.

A note on these figures: They are not directly comparable. Concentrations given in ppm (3–5 ppm, or 50–500 ppm) describe the amount of active peptide in a finished product, while percentages such as 0.5–5% generally refer to how much Matrixyl raw material — a dilute solution of the peptide in a glycerin/water base — is blended into a formulation. Because the raw material is itself dilute, a few percent of it corresponds to only a few ppm of active peptide. The pivotal Robinson trial used 3 ppm of active peptide, so the percentage figures should not be read as active-peptide concentrations; doing so would imply doses thousands of times higher than anything actually studied.

Sources

Ordered by evidence quality — the strongest first.

  1. Nanostructure and Collagen-Stimulating Activity of Cationic Pentapeptide Lipopeptides.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  2. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2005
  3. Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  4. Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  5. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  6. Mesenchymal stem cell therapy using Pal-KTTKS-enriched carboxylated cellulose improves burn wound in rat model.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  7. Self-Assembly and Wound Healing Activity of Biomimetic Cycloalkane-Based Lipopeptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  8. Boosting Cosmeceutical Peptides: Coupling Imidazolium-Based Ionic Liquids to Pentapeptide-4 Originates New Leads with Antimicrobial and Collagenesis-Inducing Activities.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  9. Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  10. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  11. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  12. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  13. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2014
  14. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2013
  15. Application of genomics to breakthroughs in the cosmetic treatment of skin ageing and discoloration.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2012

See something wrong or out of date on this page? Report it.